Insight Molecular (IMDX): רווח נקי למניה (EPS TTM)

Insight Molecular Diagnostics relies on stable, non-cyclical demand within the healthcare sector. Outsourcing production and IT solutions optimizes the turnaround time for results. The company's net income per share over the last 12 months demonstrates business resilience, while -1.50 indicates the current level. The final outcome depends on the demand for test systems and the successful certification of new pathogen panels.

Earnings per share (EPS TTM) measures the portion of profit allocated to each security over the last four quarters. Investors utilize this ratio to determine the intrinsic value of a business and forecast capital growth rates. By analyzing the trend of the rolling 12-month earnings per share, one can identify if an asset is overbought. For Insight Molecular Diagnostics (IMDX), this indicator reflects the resilience of molecular diagnostics. Stable demand for testing protects the company's profitability from economic cycles.